3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Uveal Melanoma
1
Retinal Diseases
1
Melanoma
1
Macular Degeneration
1
Choroid Diseases
1
Interventions
Nivolumab
7
Ipilimumab
4
pembrolizumab
3
Interferon alpha-2
3
relatlimab
2
Drug Therapy
2
Dacarbazine
2
sargramostim
1
salicylhydroxamic acid
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
molgramostim
1
entrectinib
1
cyclopropapyrroloindole
1
cobimetinib
1
atezolizumab
1
Vemurafenib
1
Triamcinolone Acetonide
1
Temozolomide
1
Specimen Handling
1
Sonazoid
1
Ranibizumab
1
Propranolol
1
Lenalidomide
1
Introns
1
Immunotherapy
1
Imiquimod
1
Fatty Acids, Omega-3
1
Crizotinib
1
Colony-Stimulating Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Melanoma
×
Ranibizumab
×
Clear all
NCT00811200
2009-07-02
TORR
Leiden University Medical Center
Phase 2/3
Unknown
220 enrolled